← Back to Clinical Trials
Recruiting NCT07589647

NCT07589647 Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07589647
Status Recruiting
Phase
Sponsor First Affiliated Hospital of Zhejiang University
Condition Bipolar Disorder (BD)
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2026-04-27
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
Temporal Interference StimulationSham Temporal Interference Stimulation Arm Description

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2026-04-27 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to stabilize the patients with bipolar disorder (BD) comorbid with obesity in the stable phase by using temporal interference stimulation (TIS ) intervention. It intends to investigate the changes in key metabolic molecules such as GLP-1 circadian rhythm, and further explore the molecular mechanism of their metabolic disorders.

Eligibility Criteria

Inclusion Criteria: 1. Both biological parents are of Han ethnicity; 2. Age range: 18 to 45 years old, gender not restricted; 3. Meets the clinical diagnostic criteria for bipolar disorder as stipulated in the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); 4. Body Mass Index (BMI) ≥ 28 kg/m2, or for males, waist circumference ≥ 90 cm and for females, waist circumference ≥ 85 cm; 5. HAMD-24 score \< 7 points, YMRS score \< 5 points; 6. All included researchers and their family members have given informed consent for this study. Exclusion Criteria: 221/5000 1. Individuals with other DSM-5 spectrum disorders; 2. Mental disorders caused by substance abuse (such as alcohol, drugs, etc.), and those with severe physical illnesses; 3. Those who consumed food or microecological preparations containing probiotics, prebiotics, etc. within one week before enrollment, and had a history of respiratory, urinary, digestive system infections and antibiotic use within one month before enrollment; 4. Those currently having serious suicidal thoughts or behaviors, or those with severe agitation; 5. Those who cannot follow medical advice for treatment, or those without guardians; 6. Pregnant or lactating women, or those planning to become pregnant; 7. Those who cannot complete MRI examinations due to special conditions such as having metal implants or pacemakers in their bodies.

Contact & Investigator

Central Contact

ShaoHua Hu

✉ dorhushaohua@zju.deu.cn

📞 0571-87232984

Frequently Asked Questions

Who can join the NCT07589647 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Bipolar Disorder (BD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07589647 currently recruiting?

Yes, NCT07589647 is actively recruiting participants. Contact the research team at dorhushaohua@zju.deu.cn for enrollment information.

Where is the NCT07589647 trial being conducted?

This trial is being conducted at Hangzhou, China.

Who is sponsoring the NCT07589647 clinical trial?

NCT07589647 is sponsored by First Affiliated Hospital of Zhejiang University. The trial plans to enroll 70 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology